Company news

Opus Genetics, Inc. news in 2024

Opus Genetics, Inc.'s news releases, calls and decks from 2024, newest first.

View company

Opus Genetics Receives FDA Agreement Under Special Protocol Assessment for Phase 3 Trial of APX3330 in Diabetic Retinopathy

December 18, 2024

Opus Genetics Announces Financial Results for Third Quarter 2024 and Provides Corporate Update

November 11, 2024

First Patient Enrolled in LYNX-2 Phase 3 Study Evaluating Phentolamine Ophthalmic Solution 0.75% (PS) for the Treatment of Decreased Visual Acuity Under Low Light Conditions Following Keratorefractive Surgery

April 10, 2024

Decks in 2024